A framework published by the European Association for the Study of Obesity (EASO) that addresses the pharmacological treatment of obesity and its complications. This framework proposes a new treatment algorithm that goes beyond solely focusing on weight loss, instead adopting a holistic approach by aiming to prevent or improve associated complications, such as heart failure and type 2 diabetes. The authors classify complications into “fat mass disease” and “sick fat disease” to guide personalized therapy based on the patient’s individual health background. The algorithm, which is grounded in scientific evidence published up to January 31, 2025, details specific medication recommendations, with tirzepatide and semaglutide often highlighted as first-line treatments for both substantial weight loss and managing severe complications.
McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G, Goossens GH, Monami M, Sbraccia P, Martinez-Tellez B, Woodward E, Yumuk V. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025 Oct;31(10):3229-3232. doi: 10.1038/s41591-025-03765-w. PMID: 41039115.
